1. Introduction {#sec1}
===============

In the 21st century, cancer has become one of the leading global health problems with increasing awareness among medical institutions and the general public. According to World Health Organization statistics, in 2018, there were 18.1 million new cases and 9.6 million cancer-related deaths worldwide, with the worst statistics reported for Asia with a cancer incidence and death rates of 48.4% and 57.3%, respectively \[[@B1]\]. Gastric cancer (GC) is the fifth most common and third leading cause of cancer-related death among all malignancies worldwide, with 1,033,701 new cases and 782,685 deaths reported in 2018 \[[@B1]\]. Meanwhile, the highest incidence of cancer (32.1 per 100,000 men; 13.2 per 100,000 women) and cancer-related death (15.9 per 100,000 persons) was observed in Eastern Asia \[[@B2]\]. The contribution of China to the global cancer burden is significant, especially for the four leading types of cancer (lung, liver, stomach, and esophageal cancers). Indeed, 50% of GC patients are from China and their prognosis is quite poor, with 5-year overall survival (OS) rates lower than 35% in 2013--2015 \[[@B3]\]. GC is the second and fifth most diagnosed malignancy in Chinese males and females, respectively, and one of the main causes of death in cancer patients \[[@B3], [@B4]\]. Moreover, as a major cause of GC, the higher prevalence of *Helicobacter pylori* in China (56%) compared to those of the United Kingdom (35.5%) and United States (35.6%) may be responsible for the high incidence of GC in China \[[@B5]\].

GC can be divided into early and advanced groups according to the depth of cancer invasion. Early GC can be cured by endoscopic or laparoscopic therapy as the lesion is limited to the gastric mucosa and submucosa and there is little lymph node involvement. Advanced lesions, however, often need extensive surgery, which requires distal gastrectomy and additional lymphadenectomy even with advanced systemic therapy \[[@B6], [@B7]\]. The prognosis is also significantly different; the 5-year survival rate of early GC patients (77.7%) is 6.5-fold higher than that of metastatic cancer patients (9.0%); and most advanced-stage patients survive less than 1 year \[[@B8], [@B9]\]. However, more than 80% of Chinese patients are diagnosed with advanced-stage disease due to the lack of specific symptoms \[[@B10]\]. Therefore, there is an urgent need to identify a better method for GC screening and early detection.

Recent studies have shown that circular RNA (circRNA) is a type of endogenous noncoding RNA with a stable closed loop structure that can function as a "sponge" for microRNA (miRNA) \[[@B11], [@B12]\]. Because miRNAs are involved in the development and progression of tumors, circRNAs regulating the pool of miRNAs can also be implicated in tumorigenesis. In addition, it has been shown that there is a significant difference in circRNA levels between GC tissue and adjacent noncancerous tissue. These findings suggest that circRNAs may potentially serve as novel biomarkers for GC.

This review comprehensively and concisely summarizes the classification and function of circRNAs and provides some recent findings on the emerging roles of circRNAs in GC. Finally, their potential use as diagnostic, prognostic, and therapeutic targets in GC is also discussed based on new findings from recent studies.

2. Classification of circRNAs {#sec2}
=============================

circRNAs can be classified into four types based on their different components and origin: circular exon RNAs (ecircRNAs), circular intronic RNAs (ciRNAs), exon-intron circRNAs (EIciRNAs), and transfer RNA intronic circRNAs (tricRNAs) ([Figure 1](#fig1){ref-type="fig"}).

2.1. ecircRNAs {#sec2.1}
--------------

Generally speaking, the generation of ecircRNAs can follow two paths, driven by exon skipping and intron pairing mechanisms ([Figure 1](#fig1){ref-type="fig"}). Exon skipping means that the donor splice site of the 3′ joins to the acceptor splice site of the 5′ skipped exon during pre-mRNA splicing, and finally, a head-to-tail circular structure is formed \[[@B13]\]. This phenomenon is often accompanied by the alternative splicing of pre-mRNA and is associated with the existence of core spliceosome components \[[@B13]--[@B15]\]. Exon skipping can lead to the production of single- or multiple-exon circles, which are related to the sites of splicing factors \[[@B13], [@B14]\]. In the canonical splicing process, splicing complex U1 and U2 small nuclear ribonucleoproteins (snRNPs) will bind downstream and upstream of each exon to build cross-exon interactions. With the interaction of *trans*-acting factors (such as SR proteins or heterogeneous nuclear ribonucleoproteins), these cross-exon interactions are promoted to turn into cross-intron interactions, which are essential to remove introns and build linear mRNA \[[@B15], [@B16]\]. Therefore, the activities of these *trans*-acting factors influence the levels of circRNAs and their related linear mRNAs.

The occurrence of intron pairing-driven circularization is based on intronic complementary pairing of flanking intron sequences such as Alu elements and RNA-binding proteins (RBPs), which can facilitate the formation of ecircRNAs in the mammalian pre-mRNA splicing system after removal of discontinuous intron sequences \[[@B16]--[@B19]\]. Several studies have verified that circularized exons have higher complementary Alu density in their long flanking introns than controls, and these Alu repeats can form inverted repeat Alu element (IRAlu) pairs to promote back-splicing \[[@B19], [@B20]\]. The intron pairing mechanism is not limited to IRAlu pairs, as other complementary sequences or even some RBPs (e.g., muscleblind (MBL) and quaking) can effectively influence the formation of ecircRNAs \[[@B17], [@B18], [@B20]\].

2.2. ciRNAs {#sec2.2}
-----------

ciRNAs, also known as stable intronic sequence RNAs or full-length intronic circularized RNAs, are another class of recently found circRNAs. It is well known that RNase R can degrade linear RNAs and Y-structure RNAs but has no effect on the loop portion of a lariat RNA \[[@B21]\]. In general, escape from the debranching of intron lariats is the basic reason for ciRNA generation. Several critical sequences contribute to intron circularization including the 7 nucleotide (nt) GU-rich element near the 5′ splice site, the 11 nt C-rich element close to the 3′ branchpoint, and the *RNA* lariat *debranching enzyme* Dbr1 element \[[@B21], [@B22]\]. Among these three elements, the 5′ ss-GU exhibits the best promotion effect for intron circularization; however, Dbr1 might play an indirect role or work together with other factors in this process \[[@B22]\]. In addition, RNA sequences near the 5′ splice site and C branchpoint can promote inefficient debranching, thereby enhancing the stability of ciRNAs. These key RNA elements are not abundant in regular introns or other types of circRNAs, indicating their significance in allowing an intron lariat to escape debranching \[[@B21], [@B22]\].

2.3. EIciRNAs {#sec2.3}
-------------

In EIciRNAs, introns between circularized exons are retained. EIciRNAs are primarily localized in the nucleus and associated with Pol II, suggesting that they might participate in transcriptional regulation. Indeed, several mechanisms have been proposed to explain their regulatory role in transcription, including enhancement of their parental gene expression in *cis*. It has been shown that EIciRNAs (circEIF3J and circPAIP2) can serve as potential *trans*-regulators of nonparental gene loci and even interact with U1 snRNP and Pol II through RNA-RNA interactions \[[@B23]\]. Similar findings were presented by Hu and Zhou \[[@B24]\] in a theoretical mechanistic gene model, showing that EIciRNAs can notably mediate mRNA and further protein expression.

2.4. tricRNAs {#sec2.4}
-------------

In Archaea and Eukarya, after cleavage by the transfer RNA (tRNA) splicing endonuclease complex, tRNA precursors are split into three parts: linear intron, tRNA 3′-halves beginning with a 5′-hydroxyl and 5′-halves ending in a 2′,3′-cyclic phosphate. Then, tRNA ligase interacts with the last two parts to build a mature tRNA \[[@B25], [@B26]\]. The linear intron fragment is also ligated by ligase RtcB in a head-to-tail form, thus generating stable circRNAs termed tricRNAs \[[@B27]\]. Currently, endogenous human tricRNAs (which are circular and only 16--21 nt long) cannot be verified, as they are excluded from typical RNA sequencing cDNA libraries. However, human cells have all of the necessary machinery to produce tricRNAs \[[@B27]\], which have also been identified in many human cells such as HeLa cervical cancer and human embryonic kidney 293T cells \[[@B26]\].

3. Mechanisms of circRNA Influence on GC Progression {#sec3}
====================================================

The formation of malignant tumors is closely correlated with aberrant cell proliferation, migration, and invasion. An increasing number of studies indicate that circRNAs are able to influence the biological behavior of GC cells by mediating cell cycle- or migration-related factors. Although some of their mechanisms of action remain to be clarified, the proven mechanisms are summarized below and in [Figure 2](#fig2){ref-type="fig"}.

3.1. circRNAs Acting as miRNA Sponges {#sec3.1}
-------------------------------------

The most common mechanism by which circRNAs participate in cancer progression is by acting as miRNA sponges, also known as competing endogenous RNAs (ceRNAs). In this way, they influence the posttranscriptional regulation of gene expression. Some circRNAs have more than one miRNA-binding site, which has been confirmed by several studies \[[@B12], [@B28], [@B29]\]. For example, CDR1as (antisense to the cerebellar degeneration-related protein 1 transcript), also named ciRS-7 (circRNA sponge for miR-7), contains more than 70 miRNA seed regions for miR-7, which matches and binds Argonaute proteins (AGO), allowing it to function as an excellent regulator of miR-7 \[[@B12], [@B28]\]. The zebrafish embryonic brain lacks the CDR1 locus, but steadily and highly expresses miR-7 \[[@B12], [@B30]\]. When CDR1as RNA was introduced into this model, consistent impairment of the zebrafish midbrain was observed, similar to the effect of miR-7 inhibition \[[@B12]\].

This mechanism can be widely found in GC-related circRNAs ([Table 1](#tab1){ref-type="table"}). Through binding to miRNA, they can regulate tumor-related canonical signaling pathways. The phosphatase and tensin homolog (PTEN)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway is a critical regulator of cellular activities, in which PTEN acts as a tumor suppressor that inhibits cell proliferation and metastasis \[[@B31]\]. CiRS-7 is overexpressed in GC tissues and is closely correlated with some malignant clinicopathological features of GC. Indeed, the overexpression of CiRS-7 antagonizes the level of miR-7, which leads to decreased PTEN and increased PI3K and AKT phosphorylation, eventually resulting in the oncogenic effects of the PTEN/PI3K/AKT pathway \[[@B32]\]. Conversely, circHIAT1 expression is low in GC tissues, and its overexpression suppresses activation of the PTEN/PI3K/AKT and extracellular signal-regulated kinase signaling pathways. This effect is achieved through circHIAT1 binding to miR-21, which results in the inhibition of cell proliferation and promotion of apoptosis \[[@B33]\]. Moreover, circPIP5K1A \[[@B34]\], circMAN2B2 \[[@B35]\], circNRIP1 \[[@B36]\], and circNF1 \[[@B37]\] are all upregulated in GC samples and promote GC progression through the miR-671-5p-KRT80-PI3K/AKT, miR-145-PI3K/AKT/JNK, miR-149-5p-AKT/mTOR, and miR-16-AKT axes, respectively. circ-ZFR \[[@B38]\] and circGRAMD1B \[[@B39]\] are distinctly downregulated in GC tissues and exert antitumor effects by inhibiting the miR-130a/miR-107-PTEN/p53 axis and miR-130a-3p-PTEN/p21 axis, respectively.

In addition to their influence on tumor-related signaling pathways, circRNAs can also regulate some tumor oncogenes or antioncogenes by acting as miRNA sponges. For example, the overexpression of circOSBPL10 has been verified in GC tissues and has been shown to positively correlate with tumor growth, migration, and metastasis both in vitro and in vivo. These tumorigenic actions can be explained by the circOSBPL10-miR-136-5p-WNT2 axis \[[@B40]\]. Similarly, Cheng et al. also found that upregulation of circHIPK3 promotes cell proliferation by sponging miR-124/miR-29b to regulate the human collagen genes (COL1A1, COL4A1) and CDK6 \[[@B41]\]. Furthermore, it has been shown that circNOTCH1 can function as a promoting factor for the migration, invasion, and stemness of tumors by binding to miR-449c-5p to influence Myc expression, further modulating the transcription of NOTCH1 \[[@B42]\]. In addition, circPVT1 possesses two binding sites for miR-125b and, by sponging to miR-125b, can promote expression of the E2F2 gene and facilitate GC cell proliferation \[[@B43]\]. Interestingly, circPVT1 also contributes to the chemoresistance of GC cells through the ceRNA mechanism. It has been shown that circPVT1 is highly regulated in paclitaxel- (PTX-) resistant GC tissues and cells. By attenuating the function of miR-124-3p, the level of zinc finger E-box binding homeobox 1 (ZEB1) is elevated, thereby leading to the enhanced PTX resistance of GC \[[@B44]\]. Finally, some migration-related proteins, including matrix metalloproteinase (MMP) and epithelial-to-mesenchymal transition-related markers, can be mediated through this mechanism. For instance, circNHSL1 is overexpressed in GC tissues and is positively associated with Union for International Cancer Control/tumor-node-metastasis (TNM) stage. By serving as a miR-1306-3p sponge, the highly expressed circNHSL1 removes the inhibitory effects of miR-1306-3p by acting on SIX1, resulting in increased vimentin protein expression and decreased GC growth and metastasis in vitro and in vivo \[[@B45]\]. Through the circERBB2/miR-637/MMP-19 pathway, circERBB2 positively regulates MMP-19 levels, thereby promoting cell metastasis and invasion \[[@B46]\].

3.2. circRNA Interaction with RBPs {#sec3.2}
----------------------------------

Cyclin-dependent kinase 2 (CDK2), as a member of the serine/threonine (Ser/Thr) kinase family, is a vital regulator of the cell cycle. Through binding to its partner cyclin E or A, this protein can promote the G1/S transition and DNA replication \[[@B47]\]. However, circ-Foxo3 is able to interact with CDK2 and p21 (CDK inhibitor 1) protein simultaneously, which thus induced the inhibition of p21 in CDK2 and blocked cell cycle progression \[[@B48]\].

Human antigen R (HuR) protein is well known for its ability to regulate the stability and translation of labile mRNA, which is achieved by binding to the AU-rich RNA stretches and 3′-untranslated region (UTR) of target mRNA \[[@B49]\]. In GC, circAGO2 can directly interact with HuR protein to facilitate its effect on the 3′-UTR of target genes. This in turn leads to less gene silencing and enhances tumorigenesis and tumor aggressiveness \[[@B50]\]. In addition, circ-HuR serves as an inhibitor of HuR protein by directly interacting with CCHC-type zinc finger nucleic acid binding protein, further resulting in the suppression of HuR expression \[[@B51]\]. Furthermore, circFAT1 (e2) also has the ability to suppress the proliferation, invasion, and migration of GC cells. circFAT1 (e2) can act as a sponge of miR-548g in the cytoplasm to upregulate the RUNX1 expression. This leads to the inhibition of tumorigenesis, and this effect can be accomplished by directly binding to YBX1 protein in the nucleus \[[@B52]\]. Hong et al. \[[@B53]\] reported that increased circFNDC3B promotes the migration and invasion of GC cells and affects the expression of migration-related proteins, including reduced E-cadherin, increased N-cadherin, SNAI1, and vimentin levels, which might be explained by circFNDC3B directly interacting with IGF2BP3 protein leading to the increased CD44 expression.

3.3. circRNAs in the Regulation of mRNA Transcription and Splicing {#sec3.3}
------------------------------------------------------------------

Ashwal-Fluss et al. \[[@B18]\] reported that the circularization rates of circRNAs strongly depend on the existence of canonical splice sites in bracketing exons, which can reduce the splicing efficiency of the linear transcriptome, indicating the competition between the production of circRNAs and linear splicing. Based on this mechanism, excess MBL protein can promote circMBL production, thus reducing formation of its own mRNA \[[@B18]\]. Regarding transcription regulation, apart from the aforementioned EIciRNAs, some newly discovered circRNAs also have this function. CircMRPS35, as a novel circRNA identified in GC, is negatively related to several poor clinicopathologic factors. Through attracting histone acetyltransferase KAT7, circMRPS35 elevates H4K5 acetylation in the promoter region of FOXO1 and FOXO3a genes, which further promotes the expression of FOXO1 and FOXO3a and eventually triggers the expression of p21, p27, Twist1, and E-cadherin. This process contributes to suppressing the proliferation and invasion of GC cells \[[@B54]\].

3.4. Translation of circRNAs {#sec3.4}
----------------------------

The canonical translational process is termed cap-dependent translation. In this process, the mRNA 5′-cap structure is an indispensable part, as it identifies the translation initiation complex and initiates protein synthesis \[[@B55]\]. However, circRNAs lack the 5′-cap structure, and as a result, their translation potential was ignored for a long time. In recent years, the cap-independent translation of circRNAs has been identified in eukaryotic cells, and its mechanism is mainly divided into "internal ribosome entry site- (IRES-) dependent initiation" and "N6-methyladenosine- (m^6^A-) dependent initiation" at present \[[@B56]\]. Internal ribosome entry site elements can mediate the translation initiation in a cap-independent manner, which were originally found in viruses \[[@B56]\]. The presence of an open reading frame (ORF) and STOP codon in circ-ZNF609 has led researchers to examine its protein-coding ability. During its translation initiation process, the 5′-UTR sequence is able to drive IRES-dependent translation in a spicing-dependent manner; thus, necessary factors to activate IRES elements can be loaded on a correct splicing event \[[@B57]\]. A similar mechanism can also be verified for circSHPRH \[[@B58]\] and circLINC-PINT \[[@B59]\], since their IRES activity is distinctly associated with the existence of a backsplicing junction. N6-methyladenosine (m^6^A) is widely present in eukaryotes, and its translation-promoting effect was also confirmed in mRNA and circRNA \[[@B56], [@B60]\]. Yang et al. \[[@B61]\] found that with the participation of initiation factor eIF4G2 and eIF3A, as well as m6A reader YTHDF3, m6A modification effectively facilitated the translation initiation of circRNAs in human cells. Furthermore, m^6^A-dependent translation initiation could be promoted or inhibited by methyltransferase or demethylase \[[@B61]\].

Although the function of circRNA-derived protein remains ambiguous, protein-coding ability has been found in some GC-related circRNAs. The circRNA database (circRNADb) indicates that circFNDC3B possesses a potential IRES and ORF. In addition, it has been shown that circFNDC3B can encode a peptide of approximately 25 kDa \[[@B53]\]. Besides, circPVRL3 contains IRES, ORF, and m6A modification structures, which provide a potential for its translation \[[@B62]\].

4. Applications of circRNA in GC {#sec4}
================================

4.1. circRNAs for GC Screening and Diagnosis {#sec4.1}
--------------------------------------------

Chronic gastric diseases including gastric polyps, chronic atrophic gastritis, and gastric stump after partial gastrectomy often precede the development of GC. Studies have shown that many circRNAs are differentially expressed in cells, tissues, and even the bodily fluids of people with GC, precancerous gastric lesions, and healthy individuals \[[@B63], [@B64]\]. circRNAs are quite stable in clinical samples and are associated with several GC clinicopathological factors. For some, their diagnostic value is even higher than existing diagnostic markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) \[[@B65]--[@B68]\], raising the possibility of using circRNAs to diagnose GC and evaluate patients\' prognosis. Moreover, some circRNAs have differential expression in the plasma and gastric juice of patients compared to healthy individuals and have potential to be used as noninvasive GC diagnostic biomarkers \[[@B69], [@B70]\] ([Table 2](#tab2){ref-type="table"}).

To date, three types of upregulated circRNAs, namely, hsa_circ_0066444 \[[@B71]\], hsa_circRNA_102958 \[[@B72]\], and hsa_circ_0000467 \[[@B66]\], have been identified in GC tissues that can act as diagnostic biomarkers. Their reported AUC values are 0.7328, 0.74, and 0.79, respectively. After analyzing the clinicopathological characteristics of GC patients and their tumors with respect to hsa_circ_0066444 expression in 106 GC samples, a positive association was found between its expression and lymph node metastasis \[[@B71]\].

Apart from these overexpressed circRNAs, multiple downregulated circRNAs with potential diagnostic value have been confirmed in GC tissues or blood samples. Among them, seven circRNAs have been verified both in tissues and in plasma including hsa_circ_0000190 \[[@B67]\], hsa_circ_0000181 \[[@B73]\], hsa_circ_0000520 \[[@B74]\], hsa_circ_0001821 \[[@B68]\], hsa_circ_0001017, hsa_circ_0061276 \[[@B75]\], and hsa_circ_0000419 \[[@B76]\]. The last five had higher AUC values above 0.84 (0.89, 0.87, 0.851, 0.849, and 0.840, respectively) in plasma. The AUC values for all circRNAs except hsa_circ_0000520 and hsa_circ_0000419 in tissue samples were not less than 0.75, (0.75, 0.756, 0.792, 0.871, and 0.764, respectively). Furthermore, the combination of two plasma circRNAs hsa_circ_0001017 and hsa_circ_0061276 increased the AUC value to 0.912 with 84.7% sensitivity and 96.6% specificity \[[@B75]\]. In addition, when both the plasma and tissue levels of hsa_circ_0001017 and hsa_circ_0061276 were used in combination, the AUC value reached 0.966 with a sensitivity and specificity of 95.5% and 95.7%, respectively \[[@B75]\]. Collectively, these results show the great potential of using circRNAs as biomarkers for GC diagnosis and highlight the necessity of using integrated biomarkers to elevate their diagnostic efficiency. Regarding the clinical correlation analysis, both hsa_circ_0000190 and hsa_circ_0000181 expressions in tissues were negatively associated with tumor size, CA19-9 levels, and lymphatic and distal metastases \[[@B67], [@B73]\]. The clinical values of hsa_circ_0006848 and hsa_circ_0000745 were only explored in the plasma of a smaller cohort of GC patients, and their AUC values were 0.733 and 0.683, respectively \[[@B77], [@B78]\].

In addition to those previously mentioned, 11 other circRNAs analyzed in GC tissues showed promising diagnostic potential. Among these, hsa_circ_0005654 \[[@B79]\], hsa_circ_00001649 \[[@B80]\], hsa_circ_0000096 \[[@B65]\], hsa_circ_0001895 \[[@B81]\], and hsa_circ_0003159 \[[@B82]\] had better diagnostic usefulness with AUC values of 0.927, 0.834, 0.82, 0.792, and 0.75, respectively. Combined with hsa_circ_0000096 and hsa_circ_002059, the AUC value rose to 0.91 \[[@B65]\]. The expression of hsa_circ_00001649 was associated with tumor differentiation, but hsa_circ_0000096 and hsa_circ_0003159 expression was associated with gender, distal metastasis, and TNM stage \[[@B65], [@B80], [@B82]\]. The hsa_circ_0001895 is also correlated with tumor differentiation, as well as with Borrmann type and tissue CEA expression \[[@B81]\].

Another six circRNAs including hsa_circ_0067582, hsa_circ_0005758 \[[@B83]\], hsa_circ_00014717 \[[@B11]\], hsa_circ_002059 \[[@B84]\], hsa_circ_0006633 \[[@B85]\], and hsa_circ_0130810 \[[@B86]\] have a lower diagnostic value with AUCs of 0.671, 0.721, 0.696, 0.73, 0.741, and 0.748, respectively. Among these, hsa_circ_0014717 is remarkably downregulated in 77.2% (74/96) GC tissues. In addition, it was also relatively stable in human gastric juice and its level in chronic atrophic gastritis patients was even lower than that in GC patients. These findings suggest that it can be used as a gastric juice biomarker for GC \[[@B11]\]. Finally, a meta-analysis of circRNA and GC by Jiang et al. \[[@B63]\] recently showed that although the number of studies examining circRNAs in GC plasma or saliva is limited, circRNAs have potential use as specific and accurate diagnostic biomarkers, with overall sensitivity, specificity, and AUC above 70%.

4.2. circRNAs in GC Prognosis {#sec4.2}
-----------------------------

TNM stage is the main prognostic factor for the prediction of overall survival (OS) in GC patients. Nevertheless, with the emerging precision medicine and targeted therapy, more accurate and specific prognostic indicators are needed to choose the most appropriate treatment, hopefully resulting in better outcomes.

Several studies have reported the association between circRNA and GC patient prognosis ([Table 3](#tab3){ref-type="table"}). Recently, the predictive potential of 12 circRNAs has been reported in tissues. Eight of these circRNAs were upregulated including hsa_circ_0010882 \[[@B87]\], hsa_circRNA_ATAD1 \[[@B88]\], hsa_circRNA_PVT1 \[[@B43]\], hsa_circRNA_HIPK3 \[[@B41]\], hsa_circRNA_DCAF6 \[[@B89]\], hsa_circRNA_OSBPL10 \[[@B40]\], hsa_circRNA_NHSL1 \[[@B45]\], and hsa_circRNA_NRIP1 \[[@B36]\], whereas 4 were downregulated including hsa_circRNA_LARP4 \[[@B90]\], hsa_circRNA_LMTK2 \[[@B91]\], hsa_circRNA_PVRL3 \[[@B62]\], and hsa_circRNA_CCDC9 \[[@B45]\]. In addition, a four-circRNA-based classifier with hsa_circRNA_101308 (upregulated), hsa_circRNA_104423 (downregulated), hsa_circRNA_104916 (downregulated), and hsa_circRNA_100269 (downregulated) involved was also identified.

Among these eight upregulated circRNAs (hsa_circ_0010882 \[[@B87]\], hsa_circRNA_ATAD1 \[[@B88]\], hsa_circRNA_PVT1 \[[@B43]\], hsa_circRNA_HIPK3 \[[@B41]\], hsa_circRNA_DCAF6 \[[@B89]\], hsa_circRNA_OSBPL10 \[[@B40]\], hsa_circRNA_NHSL1 \[[@B45]\], and hsa_circRNA_NRIP1 \[[@B36]\]), Kaplan-Meier analysis indicated that GC patients with high circRNA levels tend to have poorer OS, while low expression of circPVT1, circRNA_OSBPL10, circRNA_NHSL1, and hsa_circRNA_NRIP1 was also associated with lower disease-free survival (DFS) \[[@B36], [@B40], [@B43], [@B45]\]. Furthermore, univariate and multivariate Cox proportional hazards analyses revealed that overexpression of circ-DCAF6 and circPVT1 is a risk factor for GC patient survival. In addition, they are independent prognostic factors for OS and disease-free survival (DFS) in GC patients \[[@B43], [@B89]\]. Meanwhile, most of these circRNAs are associated with TNM stages and lymphatic metastasis. Downregulated circRNAs including hsa_circRNA_LARP4, hsa_circRNA_LMTK2, hsa_circRNA_PVRL3, and hsa_circRNA_CCDC9 were positively correlated with GC patient survival time, and their independent predictive potential for OS was verified through the univariate and multivariate Cox proportional hazard analyses \[[@B62], [@B90], [@B91]\]. The TNM stage was negatively associated with the expression of circPVRL3, circLTMK2, and circCCDC9 \[[@B62], [@B91]\], while a higher incidence of lymphatic metastasis was found in patients whose tumors were presented with lower circ-LARP4, circLTMK2, and circCCDC9 level \[[@B90], [@B91]\].

By examining the circRNA expression profile of 125 pairs of cancer and adjacent normal tissues of stage III GC patients, Zhang et al. \[[@B92]\] established a four-circRNA-based classifier including hsa_circRNA_101308, hsa_circRNA_104423, hsa_circRNA_104916, and hsa_circRNA_100269 in the recurrence forecast model of stage III GC and confirmed its sensitivity and specificity. In brief, patients were separated into the high-risk and low-risk groups by the cutoff value calculated using this model. According to their results, the recurrence rates in the low-risk and high-risk groups were 15.6% and 68.2%, respectively, while the AUC values were 0.763 and 0.711, respectively. In addition, when combined with traditional TNM stages, the AUC value of these two cohorts was 0.866 and 0.818, respectively \[[@B92]\]. Collectively, these results suggest that patients\' recurrence rates can be accurately calculated by constructing the model of early recurrence and even further improved through combining circRNAs with traditional TNM stages.

4.3. circRNAs in GC Treatment {#sec4.3}
-----------------------------

Chemotherapy as an indispensable adjuvant treatment strategy has been routinely applied to the advanced stage GC. To effectively suppress tumor growth and metastasis, some combination regimens can simultaneously restrain several oncogenic pathways which are recommended to use \[[@B93]\]. However, how to alleviate the chemotherapy resistance and toxicity has become an urgent issue in order to provide better treatment of GC patients. CircRNAs can influence radioresistance and chemoresistance through mediating drug accumulation, DNA repair, autophagy, target gene amplification, and the tumor microenvironment \[[@B94]\]. In GC, circAKT3 (hsa_circ_0000199) is highly expressed in cisplatin- (CDDP-) resistant GC samples and associated with multiple aggressive features including tumor size, histological grade, clinical stage, T classification, and CDDP resistance. Through the circAKT3/miR-198/PIK3R1 axis, circAKT3 distinctly improved the tolerance of GC cells to CDDP, leading to poor DFS \[[@B95]\]. Similarly, circFN1 suppressed the apoptosis of CDDP-resistant cell lines by sponging the miR-182-5p and eventually enhancing the CDDP resistance \[[@B96]\]. The paclitaxel (PTX) resistance of GC can be facilitated through the circPVT1/miR-124-3p/ZEB1 axis \[[@B44]\]. Hsa_circ_0001546 binds to miR-421, resulting in the activation of the ATM/Chk2/p53-dependent pathway, which in turn reduces the oxaliplatin (L-OPH) resistance of HGC-27 cells \[[@B97]\]. In addition, autophagy activation, which is mediated by the promotion of the circRACGAP1/miR-3657/ATG7 axis, alleviates apatinib-induced cell apoptosis and reduces the sensitivity of GC to apatinib treatment \[[@B98]\].

Exosomes, as small membrane vesicles, are secreted from various cell types and usually act as intercellular communicators. Tumor cells secrete exosomes, which function as a communication bridge between tumor cells and surrounding cells \[[@B99]\]. Several GC-related circRNAs have been found in exosomes. For instance, circNRIP1 and circ-RanGAP1 promote GC progress via the miR-149-5p/AKT1 axis and miR-877--3p/VEGFA axis, respectively. In previous studies, when their exosomal form was injected into the vein of model animals *in vivo* or incubated with GC cells *in vitro*, the enhanced tumor metastasis and migration were observed \[[@B36], [@B100]\]. Because circRNAs participate in GC progression through several mechanisms mediating the expression of tumor-related target genes or proteins and can be transported by exosomes, introducing exosomes containing circRNAs into target-therapy for tumor might have a promising future.

5. Conclusion and Perspective {#sec5}
=============================

circRNAs, as their name suggests, are equipped with a covalently closed structure and previously thought to be useless byproducts of aberrant splicing. However, there is now accumulating evidence that this new type of RNAs is characterized by various expression patterns, complicated regulatory networks, and emerging roles at multiple molecular levels including miRNA, mRNA, and protein. \[[@B101]\]. Current studies have revealed that circRNAs regulate the proliferation and migration of GC cells through several mechanisms. In addition, they have the potential to work as suitable diagnostic or prognostic biomarkers and even effective therapeutic targets. However, some issues still deserve attention to provide a better understanding of GC-related circRNAs and apply these novel molecular targets clinically as soon as possible.

First, most circRNAs modulating GC cell proliferation and progression are limited to serving as miRNA sponges. Although only a few of them have been found to interact with RBPs or regulate transcription directly, it is unknown whether circRNA-derived proteins participate in GC progress. Second, m6A as a widespread modification in eukaryotes, is able to mediate circRNA translation, but it is unknown if there are any other modifications in circRNAs that mediate the degradation of circRNAs. Third, it is well known that BCR/ABL fusion gene has been used for the diagnosis and treatment of chronic myelogenous leukemia. Similarly, circRNAs generated from fusion genes (f-circRNAs) as a new type of circRNAs also correlate with tumor progression. Guarnerio et al. \[[@B102]\] found that f-circRNAs can be generated from chromosomal translocations in various tumor types. Moreover, f-circM9 (derived from MLL/AF9 fusion gene) not only is capable of promoting cell proliferation and leukemia progression but also results in resistance to therapy. Similar results in non-small-cell lung cancer (NSCLC) have shown that both F-circSR \[[@B103]\] and F-circEA-2a \[[@B104]\], originating from the SLC34A2-ROS1 and EML4-ALK fusion gene, respectively, promote the migration of NSCLC cells. Moreover, it is possible that F-circEA-2a can serve as a novel "liquid biopsy" diagnosis biomarker for EML4-ALK-positive NSCLC. Therefore, it is worth it to explore GC-related f-circRNAs and elucidate their mechanisms and clinical value in GC tumorigenesis. Fourth, most clinical samples for GC-related circRNA studies are obtained from advanced GC patients; thus, more samples from early GC and precancerous lesions are necessary to examine the early diagnostic value of circRNAs. Fifth, most studies on circRNA in GC were based on a relatively small number of samples; therefore, further validation on a larger cohort of patients (validation set) and the use of a clinic-related circRNAs database is needed. Sixth, exosomes as intercellular communicators can be secreted from tumor cells and often carry various signals such as noncoding RNAs, mRNAs, and proteins \[[@B99]\]. Therefore, introducing exosomal circRNAs as diagnostic biomarkers and therapeutics is promising. Finally, some circRNAs have been identified to regulate the chemoresistance of GC, however, further studies are essential before they can be used clinically for GC treatment.
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![The main classification of circRNA. (a) With the interaction of TAFs (trans-acting factors), the cross-exon interactions are turned into cross-intron interactions and lead to the production of liner mRNA. (b) In the process of exon skipping, the cross-exon interactions are retained and ecircRNAs are formed. (c) The combination of the donor splice site and the acceptor splice site promotes the exon skipping. (d) Intron pairing is based on the interaction of complementary sequences or RBPs and their corresponding response elements in the long flanking intron; EIciRNAs, ecircRNAs, and ciRNAs are produced according to whether or not the introns are removed. (e) The C-rich and GU-rich elements present on opposite ends of the intron enhance the stability of intron and promote the formation of ciRNAs.](BMRI2020-2790679.001){#fig1}

![Function of circRNAs. (a) circRNAs competitively bind with miRNA which results in less mRNA degradation or translation inhibition. (b) circRNAs interact with RBPs to influence GC progression. (c) circRNAs interact with pol II and U1snRNP to regulate transcription and splicing. (d) circRNAs which encode proteins rely on the IRES-dependent or m6a-dependent translation initiation.](BMRI2020-2790679.002){#fig2}

###### 

circRNA-miRNA-mRNA/protein network in GC.

  Circular RNAs        Expression   Parental gene   Sponged miRNA     Targeted mRNA/protein       Related cell behaviors                               Ref
  -------------------- ------------ --------------- ----------------- --------------------------- ---------------------------------------------------- -------------
  hsa_circ_0006282     Up           /               miR-155           FBXO22                      Proliferation, metastasis                            \[[@B105]\]
  hsa_circ_000684      Up           /               miR-186           ZEB1                        Proliferation, migration, invasion, tube formation   \[[@B106]\]
  hsa_circRNA_001569   Up           /               miR-145           NR4A2                       Proliferation, apoptosis,                            \[[@B107]\]
  hsa_circRNA_102958   Up           /               miR-585           CDC25B                      Proliferation, migration, invasion,                  \[[@B108]\]
  hsa_circRNA_104433   Up           ARPC1B          miR-497-5p        CDC25A                      Proliferation, apoptosis                             \[[@B109]\]
  hsa_circ_0000291     Up           CD44            miR-183           ITGB1                       Proliferation, migration                             \[[@B110]\]
  hsa_circ_0017639     Up           SFMBT2          miR-224-5p        USP3                        Proliferation, migration                             \[[@B111]\]
  hsa_circ_0092306     Up           chr 11          miR-197-3p        PRKCB                       Proliferation, apoptosis, migration, invasion,       \[[@B112]\]
  Circ-ATAD1           Up           ATAD1           miR-140-3p        YY1/PCIF1                   Proliferation, apoptosis, migration, invasion        \[[@B88]\]
  Circ-ATXN7           Up           ATXN7           miR-4319          ENTPD4                      Proliferation, apoptosis, migration                  \[[@B113]\]
  circ-PIP5K1A         Up           PIP5K1A         miR-671-5p        KRT80                       Proliferation, migration, invasion, EMT process      \[[@B34]\]
  circ-ERBB2           Up           ERBB2           miR-503,miR-637   CACUL1, MMP-19              Proliferation, apoptosis, migration, invasion        \[[@B46]\]
  circ-NHSL1           Up           NHSL1           miR-1306-3p       SIX1/vimentin               Migration, invasion                                  \[[@B45]\]
  circ-PVT1            Up           PVT1            miR-125b          E2F2                        Proliferation                                        \[[@B43]\]
  circ-HIPK3           Up           HIPK3           miR-124/29b       COL1A1/COL4A1/CDK6          Proliferation                                        \[[@B41]\]
  circ-OSBPL10         Up           OSBPL10         miR-136-5p        WNT2                        Proliferation, migration, invasion                   \[[@B40]\]
  circ-NOTCH1          Up           NOTCH           miR-449c-5p       MYC/NOTCH1                  Proliferation, migration, invasion                   \[[@B42]\]
  circ-NRIP1           Up           NRIP1           miR-149-5p        AKT1/mTOR pathway           Proliferation, migration, invasion                   \[[@B36]\]
  ciRS-7               Up           Cdr1as          miR-7             PTEN/PI3K/AKT pathway       Proliferation, migration, invasion                   \[[@B32]\]
  circ-MAN2B2          Up           MAN2R2          miR-145           PI3K/AKT/JNK pathway        Proliferation, migration                             \[[@B35]\]
  circ-HIAT1           Down         HIAT1           miR-21            PTEN/PI3K/AKT/ERK pathway   Proliferation, apoptosis, EMT process                \[[@B33]\]
  circ-ZFR             Down         ZFR             miR-130a/107      PTEN                        Proliferation, apoptosis                             \[[@B38]\]
  circ-YAP1            Down         YAP1            miR-367-5p        p27 ^Kip1^                  Proliferation, invasion                              \[[@B114]\]
  circ-RHOBTB3         Down         RHOBTB3         miR-654-3p        p21                         Proliferation, apoptosis                             \[[@B115]\]
  circ-LARP4           Down         LARP4           miR-424-5p        LATS1                       Proliferation, invasion                              \[[@B90]\]
  circ-FAT1 (e2)       Down         FAT1            miR-548 g         RUNX1                       Proliferation, invasion, migration.                  \[[@B52]\]
  circ-CCDC9           Down         CCDC9           miR-6792-3p       CAV1                        Proliferation, migration, invasion                   \[[@B116]\]
  hsa_circ_0001368     Down         KLHL24          miR-6506-5p       FOXO3                       Proliferation, invasion                              \[[@B117]\]

###### 

Diagnostic efficiency of circRNAs in GC.

  circRNAs             Samples                                                                        Clinical association                                                       Diagnostic value   Sample size   Ref                                
  -------------------- ------------------------------------------------------------------------------ -------------------------------------------------------------------------- ------------------ ------------- -------- ----------- ------- ----- ------------
  Oncogenic                                                                                                                                                                                                                                          
  hsa_circ_0066444     Tissues                                                                        Lymphatic metastasis                                                       0.7075             0.6887        0.7328   ---         106     106   \[[@B71]\]
  hsa_circRNA_102958   Tissues                                                                        TNM stage                                                                  0.61               0.86          0.74     ---         30      30    \[[@B72]\]
  hsa_circ-0000467     Tissues                                                                        TNM stage                                                                  0.705              0.648         0.790    ---         51      51    \[[@B66]\]
  Antioncogenic                                                                                                                                                                                                                                      
  hsa_circ_0067582     Tissues                                                                        Tissue CEA level and stages                                                0.552              0.750         0.671    10.61       96      96    \[[@B83]\]
  hsa_circ_0005758                                                                                    CEA level and perineural invasion                                          0.750              0.677         0.721    10.20                     
  hsa_circ_0003159     Tissues                                                                        Gender, distal metastasis, and TNM stage                                   0.852              0.565         0.75     12.31       108     108   \[[@B82]\]
  hsa_circ_0005654     Tissues                                                                        ---                                                                        ---                ---           0.927    ---         68      68    \[[@B79]\]
  hsa_circ_00001649    Tissue                                                                         Pathological differentiation                                               0.711              0.816         0.834    0.2269225   76      76    \[[@B80]\]
  hsa_circ_0000096     Tissues                                                                        Gender, invasion, and TNM stage                                            0.88               0.56          0.82     12.9        101     101   \[[@B65]\]
  hsa_circ_0014717     Tissues                                                                        Tumor stage, distal metastasis, tissue CEA, and CA19-9 expression          0.5938             0.8125        0.696    12.14       96 GC   96    \[[@B11]\]
  hsa_circ_0001895     Tissues                                                                        Tumor differentiation, Borrmann type, and tissue CEA expression            0.678              0.857         0.792    9.53        96 GC   96    \[[@B81]\]
  hsa_circ_002059      Tissues                                                                        Distal metastasis, TNM stage, gender, and age                              0.81               0.62          0.73     12.9        101     101   \[[@B84]\]
  hsa_circ_0006633     Tissues                                                                        Distal metastasis and tissue CEA level                                     0.60               0.81          0.741    8.17        96      96    \[[@B85]\]
  hsa_circ_0130810     Tissues                                                                        TNM stage and lymphatic metastasis                                         0.7742             0.6800        0.7481   1.443       28      28    \[[@B86]\]
  hsa_circ_0006848     Plasma                                                                         Tumor differentiation and tumor size                                       ---                ---           0.733    ---         30      30    \[[@B77]\]
  hsa_circ_0000745     Plasma                                                                         TNM stage                                                                  0.855              0.45          0.683                60      60    \[[@B78]\]
  hsa_circ_0000190     Tissues,                                                                       Tumor diameter, lymphatic and distal metastasis, TNM stage, and CA19-9     0.721              0.683         0.75     6.83        104     104   \[[@B67]\]
  Plasma               CEA                                                                            0.414                                                                      0.875              0.60          3.07     104         104           
  hsa_circ_0000181     Tissues, plasma                                                                Tumor size, lymphatic metastasis, distal metastasis, and CA19-9            0.990              0.852         0.756    9.40        115     115   \[[@B73]\]
                       Tumor differentiation and CEA level                                            99.0%                                                                      20.6%              0.582         7.27     102         105           
  hsa_circ_0000520     Tissues,                                                                       TNM stage                                                                  0.5357             0.8571        0.6129   ---         56      56    \[[@B74]\]
  Plasma               CEA expression                                                                 0.8235                                                                     0.8444             0.8967        ---      45          17            
  hsa_circ_0001821     Tissues,                                                                       Tumor depth and lymph node metastasis                                      ---                ---           0.792    ---         80      80    \[[@B68]\]
  Plasma               ---                                                                            ---                                                                        ---                0.872         ---      30          30            
  hsa_circ_0001017     Tissues,                                                                       Age, tumor size, invasion, TNM stages, distal metastasis, and CEA levels   0.794              0.811         0.871    ---         121     121   \[[@B75]\]
  Plasma               Gender, tumor size, differentiation, and distal metastasis                     0.676                                                                      0.897              0.851         ---                                
  hsa_circ_0061276     Tissues,                                                                       Age, tumor size, TNM stages, distal metastasis, and CEA levels             0.913              0.507         0.764    ---                       
  Plasma               Gender, tumor size, differentiation, and CEA levels                            0.758                                                                      0.959              0.849         ---                                
  hsa_circ_0000419     Tissues,                                                                       Borrmann type and differentiation grade                                    0.552              0.677         0.642    8.14        96      96    \[[@B76]\]
  Plasma               Tumor stage, lymphatic and distal metastasis, venous and perineural invasion   0.682                                                                      0.884              0.840         4.9      44          43            

Sens: sensitivity; Spec: specificity.

###### 

Prognosis-related circRNAs in GC.

  circRNAs                        Number of patients   Samples   Dysregulation                                             Correlated clinicopathologic features                                                                   Clinical values                Ref
  ------------------------------- -------------------- --------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------ -------------
  hsa_circ_0010882                49                   Tissues   Upregulated                                               TNM stage and tumor size                                                                                Poor OS                        \[[@B87]\]
  circ-ATAD1                      72                   Tissues   Upregulated                                               Tumor size, invasion, lymphatic metastasis, TNM stage                                                   Poor OS                        \[[@B88]\]
  circ-HIPK3                      63                   Tissues   Upregulated                                               T stage and Ming\'s classification                                                                      Poor OS                        \[[@B41]\]
  circ-DCAF6                      62                   Tissues   Upregulated                                               ---                                                                                                     Poor OS                        \[[@B89]\]
  circPVT1                        187                  Tissues   Upregulated                                               ---                                                                                                     Poor OS and DFS                \[[@B43]\]
  circ-OSBPL10                    70                   Tissues   Upregulated                                               T stage, TNM stage, and tumor location (cardia GC show higher expression than noncardia GC)             Poor OS and DFS                \[[@B40]\]
  circ-NHSL1                      93                   Tissues   Upregulated                                               UICC stages, pathological T stages, lymphatic metastasis, distant metastasis, and grades                Poor OS and DFS                \[[@B45]\]
  circ-NRIP1                      110                  Tissues   Upregulated                                               Tumor size, lymphatic invasion                                                                          Poor OS and DFS                \[[@B36]\]
  circ-LARP4                      387                  Tissues   Downregulated                                             Tumor size and lymphatic metastasis                                                                     Better OS                      \[[@B90]\]
  circ-LMTK2                      111                  Tissues   Downregulated                                             TNM stage and lymphatic metastasis                                                                      Better OS                      \[[@B91]\]
  circ-PVRL3                      62                   Tissues   Downregulated                                             TNM stage                                                                                               Better OS                      \[[@B62]\]
  circ-CCDC9                      48                   Tissues   Downregulated                                             Tumor size, lymph node invasion, and TNM stage                                                          Better OS                      \[[@B116]\]
  Four-circRNA-based classifier   125                  Tissues   Circ-101308↑, Circ-104423↓, Circ-104916↓, Circ-100269 ↓   Effectively predict the early recurrence of stage III GC. (with HR value and ROC curve were provided)   Recurrence-related biomarker   \[[@B92]\]
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